Alcohol-linked cirrhosis and heart failure disability set to climb sharply by 2050

The disability burden associated with alcohol-related cirrhosis complicated by heart failure is projected to rise substantially by 2050 across Central Europe, Eastern Europe and the United States, according to new research due to be presented at UEG Week 2026 in Barcelona. The study, which draws on Global Burden of Disease data spanning 1990 to 2023, offers one of the most detailed trans-Atlantic pictures yet of how years lived with disability from this combined liver and heart condition have evolved, and how they are likely to develop over the coming decades if current trends persist.

Researchers analysed years lived with disability, or YLD, a measure that captures the time people spend living with ill health or disability rather than dying prematurely from it. By examining YLD rates by age and sex across Central Europe, Eastern Europe, Western Europe and the United States, the team was able to chart not only the overall scale of the burden but also the demographic groups and regions carrying the heaviest load. They then modelled how that burden could change through to 2050, producing projections that reveal sharply divergent trajectories on either side of the Atlantic.

The analysis found that the burden has already increased considerably in all four regions since 1990, with particularly pronounced increases among older adults and men. Between 1990 and 2023, Western Europe consistently recorded the highest YLD rate, with an increase of 28.6 percent over the period. However, the steepest relative increases occurred in Central and Eastern Europe, where rates rose by 82.9 percent and 74.7 percent respectively. The United States recorded a 38.5 percent increase over the same three decades.

The projections for the period to 2050 point to further substantial growth in three of the four regions studied. Compared with 2023, the YLD burden is modelled to increase by 65.4 percent in the United States, 49.6 percent in Central Europe and 66.6 percent in Eastern Europe. Western Europe stands out as the exception, with a projected decline of 19.0 percent. The contrast between Western Europe’s anticipated improvement and the steep climbs forecast elsewhere is one of the study’s most striking findings, and the researchers argue that understanding what is driving that difference could hold lessons for regions facing rising burdens.

Age emerges as a defining factor in the distribution of this disability burden. Across all four regions, people aged 70 and over experienced YLD rates 10 to 16 times higher than those aged 15 to 49 years. The ageing of populations is expected to amplify this effect. In the United States, older adults are projected to experience a particularly pronounced increase, with the YLD rate among those aged 70 and over predicted to reach 1.893 per 100,000 by 2050, a figure 73.7 percent higher than in 2023. As life expectancy rises, more people are living long enough to accumulate the cumulative organ damage that links heavy alcohol use to both cirrhosis and heart failure.

Sex differences are equally marked. Men experienced a consistently greater burden than women in all four regions, with male-to-female YLD ratios ranging from 1.86 in Eastern Europe to 3.27 in Central Europe. This pattern reflects long-established differences in alcohol consumption levels and drinking patterns between men and women, but it also signals where prevention efforts may need to be targeted most intensively. The combination of male predominance and concentration among older adults means the projected growth in burden will fall disproportionately on specific, identifiable groups, which the researchers say should inform how health systems plan services.

Study author Dr Ashesh Das emphasised that the trends are far from uniform. “Our findings show that the disability burden associated with alcohol-related cirrhosis complicated by heart failure has increased substantially over the past three decades, but the pattern is far from uniform,” he said. “Older adults and men are particularly affected, and the marked differences between regions show why a one-size-fits-all approach to prevention and healthcare planning is unlikely to be enough.” His comments underline the central message of the research: that effective responses must be tailored to regional and demographic realities rather than applied generically.

The clinical backdrop to these figures is the growing scientific interest in the interrelationship between the heart and liver along shared disease trajectories, often referred to as the heart-liver axis. Alcohol-related liver disease remains a major public health challenge in its own right, but its complications extend well beyond the liver. The World Health Organization notes that alcohol is causally linked to more than 200 diseases and health conditions, including liver cirrhosis and cardiovascular disease. The WHO European Region has the highest level of alcohol consumption globally, and alcohol is the most common cause of death from liver disease in Europe. When cirrhosis is complicated by heart failure, the demands on patients and on health services multiply, spanning hepatology, cardiology and wider care provision.

Looking ahead, Dr Das warned that the projections carry a clear policy implication. “The projections suggest that without effective prevention and appropriate healthcare planning, the burden could continue to grow substantially in several regions over the coming decades,” he said. “With populations ageing, health systems need to consider the combined demands that cirrhosis and heart failure can place on hepatology, cardiology and wider care services.” The modelling suggests that the coming decades will test the capacity of health systems in the United States, Central Europe and Eastern Europe to manage a growing population of patients whose conditions straddle two medical specialties simultaneously.

The researchers emphasise the importance of strategies to reduce alcohol-related harm as the most direct lever for changing these trajectories. The WHO identifies measures including alcohol taxation and restrictions on alcohol availability and marketing as important approaches to reducing alcohol-related harm. Dr Das concluded that the findings underline the need to strengthen such strategies, particularly as populations age, and that the contrasting trajectory projected for Western Europe highlights the need to understand what may be driving differences between regions, and whether lessons can be applied elsewhere. The study, a systematic analysis of years lived with disability from the Global Burden of Disease 2023 study examining the trans-Atlantic burden of alcohol-attributable cirrhosis and its contribution to heart failure in the United States versus Europe from 1990 to 2023, will be presented at UEG Week 2026 on 19 October in Barcelona, where the European Association for the Study of the Liver’s Love Your Liver initiative will for the first time offer free liver health checks to congress delegates, venue staff and members of the local community, reflecting a shared ambition to extend the impact of medical congresses beyond the venue and into surrounding neighbourhoods.

Subject of Research: Projected disability burden of alcohol-related cirrhosis complicated by heart failure across Europe and the United States to 2050

Article Title: Disability burden linked to alcohol-related cirrhosis and heart failure projected to rise sharply by 2050

Article References: Disability burden linked to alcohol-related cirrhosis and heart failure projected to rise sharply by 2050. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: alcohol-related cirrhosis, heart failure, years lived with disability, Global Burden of Disease, UEG Week 2026, heart-liver axis, alcohol harm prevention, ageing populations, health projections 2050, liver disease, cardiovascular disease, public health